Friends of Bryce Reeves
Bryce is a leader fighting for ALL his constituents and knows that people always come before politics.
While the Biden Administration and Leftist Liberals allow China to walk all over America, I have made it my mission to put a stop to this “American Last Agenda”. That is why I have personally carried and PASSED legislation to declare Chinese Fentanyl a weapon of Terrorism, sponsored and PASSED legislation to make it illegal for the Chinese government to purchase land in Virginia, and carried and PASSED legislation establishing a trade office with our economic partner and the freedom loving people of Taiwan. On May 6th vote for the candidate with a proven record of making Virginia Safer.
↗ View in Meta Ad Library (the live creative — image/video/layout)
| Overall score | 40.3/100 |
| Spend / Reach / Long. / Eff. | 23.7 · 68.1 · 2.2 · 67.3 |
| Spend range | USD 400–499 |
| Impressions | 40,000 – 44,999 |
| CPM (≈ $/1k impr) | USD 10.58 |
| Est. audience size | 100,001 – 500,000 |
| Days live | 9 (2023-04-26 → 2023-05-05) |
| Created | 2023-04-26 |
| Creative variants | 1 body · 1 headline |
| Platforms | facebook, instagram |
| Languages | — |
| Candidate | VA — Bryce Reeves |
| Surfaced by | “senate:Bryce Reeves” |
| Issue | foreign policy defense |
| Framing | contrast comparison |
| Message type | persuasion |
| Emotional appeal | fear |
| Production tier | semi pro |
| Who pictured | candidate, opponent |
| Symbols | us flag, border, money cash |
| Call to action | vote |
| Standout element | Yellow X crossed over a photo of Biden shaking hands with Xi Jinping labeled 'Biden Admin America Last' |
| Tactic | The ad uses a tri-point legislative record combined with an enemy-framing visual (Biden-Xi photo with yellow X) to position Reeves as a proven China fighter, leveraging fear of foreign interference and national sovereignty to drive vote intent. |
| Virginia | 100.0% |
| Maryland | 0.0% |
| West Virginia | 0.0% |
| Pennsylvania | 0.0% |
| 25-34 · unknown | 0.0% |
| 65+ · unknown | 0.1% |
| 45-54 · unknown | 0.1% |
| 35-44 · unknown | 0.1% |
| 55-64 · unknown | 0.2% |
| 35-44 · female | 4.3% |
| 25-34 · male | 5.0% |
| 45-54 · female | 4.5% |
| 25-34 · female | 4.6% |
| 45-54 · male | 9.9% |
| 65+ · male | 19.0% |
| 55-64 · female | 9.4% |
| 65+ · female | 19.3% |
| 55-64 · male | 15.1% |
| 35-44 · male | 8.4% |